{
  "abstract": "Introduction: Real-world evidence on long-term effectiveness and safety of oral Janus kinase (JAK) inhibitors in atopic dermatitis (AD) remains limited. This study evaluated sustained long-term clinical and patient-reported disease control and safety during continuous treatment with upadacitinib 30 mg or baricitinib 4 mg.\n\nMethods: This monocentric retrospective study included adults with moderate-to-severe AD treated at IRCCS Humanitas Research Hospital. Eligible patients had baseline assessments and completed longitudinal follow-ups while remaining on their assigned JAK inhibitor. Outcomes were assessed through week 260 for upadacitinib and week 312 for baricitinib and included Eczema Area and Severity Index (EASI) 75/90/100, EASI ≤ 7/≤ 3, Investigator Global Assessment (IGA) 0/1, mean EASI, Peak Pruritus Numerical Rating Scale (PP-NRS), Sleep Disturbance Numerical Rating Scale (SD-NRS) improvement and remission endpoints, and safety. Between-treatment comparisons were considered exploratory only.\n\nResults: The long-term cohort included 41 patients: 34 received upadacitinib and 7 baricitinib. At week 260, EASI 75, EASI 90, EASI ≤ 7, and EASI ≤ 3 were achieved by 97.1%, 91.2%, 100.0%, and 91.2% of upadacitinib-treated patients, respectively. In the baricitinib group, EASI 75 was maintained by all patients from week 32 to week 312, and EASI 90, EASI ≤ 7, and EASI ≤ 3 were achieved by all patients at week 312. IGA 0/1 and mean EASI indicated sustained low disease activity during follow-up. At week 260, ΔPP-NRS ≥ 4 and ΔSD-NRS ≥ 4 were maintained in 82.4% and 73.5% of upadacitinib-treated patients and in 85.7% and 71.4% of baricitinib-treated patients, with corresponding baricitinib rates maintained at week 312. Adverse events were infrequent, with no serious adverse events, treatment interruptions, or permanent discontinuations in the long-term cohort.\n\nConclusions: In selected patients remaining on continuous treatment, upadacitinib and baricitinib were associated with sustained long-term clinical and patient-reported control of moderate-to-severe AD. Larger prospective studies are needed to clarify outcomes after dose reduction or discontinuation and the potential for deeper disease remodeling.\n\nSupplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13555-026-01940-6.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI Italy",
    "Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Francesco D’Oria",
      "orcid": "0009-0001-3446-6648"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Costanza Falcidia",
      "orcid": "0009-0001-4009-0544"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Giulio Foggi",
      "orcid": "0009-0006-0527-706X"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Matteo Bianco",
      "orcid": "0009-0003-9859-4475"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Ruggero Cascio Ingurgio",
      "orcid": "0009-0000-1438-9553"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Angela Alfano",
      "orcid": "0009-0004-6269-448X"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Luciano Ibba",
      "orcid": "0000-0002-7876-4866"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Mario Valenti",
      "orcid": "0000-0001-9140-9263"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Antonio Costanzo",
      "orcid": "0000-0001-9697-2557"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Alessandra Narcisi",
      "orcid": "0000-0002-1938-8581"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Luigi Gargiulo",
      "orcid": "0000-0002-6051-1676"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/732tbb6ecqc4t.bib",
  "cited_by": 0,
  "doi": "10.1007/s13555-026-01940-6",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13696667/",
  "id": "732tbb6ecqc4t",
  "issns": [
    "2193-8210",
    "2190-9172"
  ],
  "landing_url": "https://doi.org/10.1007/s13555-026-01940-6",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "lcc",
      "RL1-803"
    ],
    [
      "openalex",
      "2708|Dermatology and Skin Diseases"
    ]
  ],
  "openalex": "W7215078628",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s13555-026-01940-6.pdf",
  "pmcid": "PMC13696667",
  "pmid": "42823606",
  "published": "2026-10-01",
  "publisher": "Springer",
  "ris": "https://research.draconitic.com/paper/732tbb6ecqc4t.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:59Z",
      "native_id": "PMC13696667",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s13555-026-01940-6"
    },
    {
      "first_seen": "2026-10-30T13:45:38Z",
      "native_id": "d217075caea140c596cbd01f79047b6d",
      "source": "doaj",
      "url": "https://doi.org/10.1007/s13555-026-01940-6"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2708|Dermatology and Skin Diseases",
      "subfield": "general"
    }
  ],
  "title": "Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study",
  "title_text": "Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:45:38Z",
  "url": "https://research.draconitic.com/paper/732tbb6ecqc4t",
  "venue": "Dermatology and Therapy",
  "versions": []
}